Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Hims & Hers Health, Inc. Class A Common Stock (NY:HIMS)

61.99 -2.66 (-4.11%)
Streaming Delayed Price Updated: 11:44 AM EDT, May 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Hims & Hers Health, Inc. Class A Common Stock

< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
27 28 Next >
A New Name in Weight Loss Drugs
Novo Nordisk and Eli Lilly have soared on the popularity of GLP-1 weight loss drugs. Now Hims & Hers is trying to get in on the action with a more available and affordable option. 
Via The Motley Fool
LifeMD Can Surge on Its GLP-1 Offerings
LifeMD is a leading telehealth provider that investors should take note of; the company is entering the GLP-1 market, and its stock could soar as a result 
Via MarketBeat
Soaring Eli Lilly Stock Could Climb Another 24% According to a Wall Street Analyst. Is the Stock a Buy Now?
Plowing $9 billion into a manufacturing facility could help a successful tirzepatide launch reach new heights. 
Via The Motley Fool
The Ultimate Growth Stock to Buy With $20 Right Now
I challenge you to name another $20 stock with more long-term potential. 
Via The Motley Fool
7 Stocks to Dominate in the Next Economic Upturn
Discover the top stocks to buy for the next economic upturn, carefully selected for their robust growth potential. 
Via InvestorPlace
Unpacking the Latest Options Trading Trends in Hims & Hers Health
Via Benzinga
Navigating 10 Analyst Ratings For Hims & Hers Health
Via Benzinga
Hims & Hers Is Changing the Game
GLP-1s could be the product that pushes Hims & Hers over the edge to mainstream adoption. 
Via The Motley Fool
Move Over Ozempic! 3 New GLP-1 Drugs and Products Coming Soon.
The search for the next GLP-1 drugs that will be blockbuster winners during the next market cycle is on, and here are three contenders. 
Via InvestorPlace
The Growth Stock Shuffle: 2 to Ditch and 1 to Own
Investing in growth stocks requires a keen eye for profitability. Ditch these two unprofitable stocks and embrace this telehealth winner. 
Via InvestorPlace
EXCLUSIVE: Roundhill Investments Launches Weight Loss ETF For Exposure To Blockbuster Drugs Like Ozempic
Roundhill CEO Dave Mazza says investors "can't just buy a basket of big pharma names or a broad-based biotech ETF and call it a day." 
Via Benzinga
Topics ETFs
Meme Stocks GameStop, AMC Fade In Interest After Roaring Kitty Exit: Here's What WallStreetBets Is Eyeing Next
Retail traders could be shifting away from meme stocks to several other stocks seeing strong interest on WallSteetBets. 
Via Benzinga
Hims & Hers Health Options Trading: A Deep Dive into Market Sentiment
Via Benzinga
Is Hims & Hers Health Stock a Buy?
A six-point argument that shares are a table-pounding opportunity worth scooping up now. 
Via The Motley Fool
2 Incredible Growth Stocks to Buy Hand Over Fist
These two healthcare growth stocks could have a lot more room to run. 
Via The Motley Fool
Why Hims & Hers Health Stock Popped 17.1% Today
Strong earnings have sent this healthcare company higher today. 
Via The Motley Fool
HIMS Stock Alert: Hims & Hers Shares Rocket on Weight Loss Injections
HIMS stock is catching a bid after Hims & Hers announced that it would begin providing access to GLP-1 weight-loss injections. 
Via InvestorPlace
Tech Surge Boosts Nasdaq To Record Highs
The Nasdaq Composite Index is up triple digits and marking new record highs, thanks to rising tech stocks. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Stocks, Gold Reach New Record Highs, Cruise Stocks Rally, GameStop Sinks: What's Driving Markets Monday?
Wall Street rallies on Monday as major US indices reach fresh record highs. Metal commodities surge, Treasury yields stay stable. Cruise stocks soar. 
Via Benzinga
Why Virios Therapeutics Shares Are Trading Lower By Around 48%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Wellness Platform Hims & Hers Health Adds GLP-1 Injections For Weight Loss, Stock Soars
Hims & Hers Health expands its weight loss offerings with GLP-1 injections and oral medication kits. Pricing starts at $79/month. 
Via Benzinga
Overseas Shipholding, Micron, Squarespace, Incyte And Other Big Stocks Moving Higher On Monday
Via Benzinga
Hims & Hers Announces Access to GLP-1 Injections, Passing Cost Savings Onto Customers
From Hims & Hers
Via Business Wire
Stock Market Mayhem: 3 Companies Ready to Shake Things Up
As the stock market heats up, consider investing in these three disruptive stocks to buy, likely to offer substantial long-term gains. 
Via InvestorPlace
Hims & Hers Welcomes Anja Manuel, Foreign Policy Expert, Domestic Regulations Advisor, and Former Diplomat to its Board of Directors
From Hims & Hers
Via Business Wire
3 Stocks That Suddenly Drew in Options Traders
Three discounted stocks caught the attention of call option buyers last week, and they have Wall Street analysts to back them through double-digit upside. 
Via MarketBeat
5 Medical Info Systems Stocks To Buy For Stable Returns
The medical info systems industry is thriving due to the growing demand for contactless services. Amid this environment, here are some stocks in the industry that may see stable returns in 2024. 
Via Talk Markets
Hims & Hers Health Shares Climb After News of Double-Digit Revenue Growth. Is It Too Late to Buy the Stock?
The stock is one of the cheapest high-growth stocks around. 
Via The Motley Fool
Why Beyond Shares Are Trading Lower By Over 20%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
27 28 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.